La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Enveric Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Enveric Biosciences..

Enveric Biosciences (NASDAQ:ENVB) Azioni, Catena delle Opzioni

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Enveric Biosciences Inc

In the world <a href="https://www.benzinga.com/general/sports-betting">of sports betting, </a>there are bets on one team winning, bets on player props and various other options, alongside what one 24-year-old has found fame from: parlaying multiple teams to win championships.
What Happened: An unemployed 24-year-old who doesn't consider himself a big sports bettor is on pace to win a huge six-figure profit from a $13 bet placed with sportsbook DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), providing the potential opposite big win from <a href="https://www.benzinga.com/news/25/06/45936603/jay-z-loses-1-million-betting-on-nba-finals-how-the-indiana-pacers-spoiled-rappers-3-33-million-payd">Jay Z&#8217;s $1 million loss. </a>
Months ago, Drew Hirschman <a href="https://dknetwork.draftkings.com/2025/06/12/massive-270k-parlay-bet-on-draftkings-sportsbook-hinges-on-thunder-oilers-championships/#:~:text=Drew%20Hirschman%2C%2024%2C%20placed%20a,Cup%20to%20cash%20the%20ticket.">placed </a>a $13 wager with the sportsbook for the following teams to win championships in their respective leagues:
<ul class="wp-block-list">
<li>Los Angeles Dodgers (MLB): Done</li>
<li>New York Liberty (WNBA): Done</li>
<li>Philadelphia Eagles (NFL): Done</li>
<li>Edmonton Oilers (NHL): In process</li>
<li>Oklahoma City Thunder (NBA): In process</li>
</ul>
Three of the five legs are complete and amazingly enough, the other two teams find themselves in the championship series, mere games away from helping cash the huge parlay.
When the wager was made, it had less than a 0.01% chance of hitting. Cashout offers from DraftKings have shown that the odds of Hirschman winning the parlay have been above 30%.
The Oilers currently trail the Florida Panthers 3-2 in the best-of-seven Stanley Cup Finals. The Oklahoma City Thunder are tied 2-2 with the Indiana Pacers in the NBA Finals.
If the Oilers and Thunder win, the bet pays out $270,761.40, a huge profit from a $13 bet.
Hirschman has received cashout offers of up to $123,000 with the most recent public amount <a href="https://x.com/DKSportsbook/status/1933570132380402134">listed </a>at $107,591.51 before the Oilers lost game five on Saturday.
The bettor can likely take a cash out offer of less than $100,000, let the bet ride or hedge his bets by placing wagers on other outcomes to secure a payout no matter what happens.
Hirschman's bet has turned to DraftKings regularly profiling his parlay and doing video interviews. Bleacher Report (@br_betting) is flying him to game locations to make betting content.
Perhaps the craziest part of the parlay is the unlikeliest leg already hit. At the time of the bet, the Dodgers were +300 to win, the Liberty were +190 and the Eagles were +1700. The remaining legs had odds of +850 for the Thunder and +850 for the Thunder.
"I got home from work and I saw Saquon (Barkley) went to the Eagles and I'm a Giants fan and I was like, ‘This guy is too talented, this team is too good, I can't imagine they don't go on a deep run.' So, I did some crafting and came up with this," Hirschman <a href="https://nypost.com/2025/06/10/betting/recent-grad-has-life-changing-270000-bet-riding-on-oilers-thunder-championships/">told </a>the New York Post.
Read Also: <a href="https://www.benzinga.com/general/sports/25/05/45303072/draftkings-q1-earnings-highlights-revenue-miss-eps-miss-guidance-cut-after-bettors-beat-the-house">DraftKings Q1 Earnings Highlights: Revenue Miss, EPS Miss, Guidance Cut After Bettors Beat The House</a>
What's Next: Hirschman's entry into sports betting content could be something to watch as he looks for a new job.
"I am currently unemployed, looking for jobs. Living with my parents in Suffern (New York). This gives me a little gap where I don't have to feel too pressured," Hirschman told the New York Post.
The bettor said he hedged his bet a "bit" with Caesars Sportsbook, wagering more than $50,000 on other outcomes.
"I definitely emptied my bank accounts."
Hirschman said his dad is a "math guy" and helped come up with a plan and helped come up with the funds.
If the Oilers come back to win the seven game series and the Thunder win two more games against the Pacers, Hirschman's parlay will cash and provide over $200,000 in profit for the recent college graduate.
"Going to max out the 401k, max out the Roth. Add to the emergency fund. Going to have a little fun. Maybe a little vacation. Bring the boys out to dinner. Bring my family out to dinner."
Hirschman said his main goal if he wins is "don't blow it."
The Thunder and Pacers meet again for game five Monday night at 8:30 p.m. in a game that will air on Walt Disney Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) ABC.
Despite the series being tied, the Thunder remain huge favorites with odds of -450 to win the series with the Pacers listed at +350.
The Oilers are the wild card for Hirschman now with odds of +280 to win the series, needing to win game six to tie the series and a win in game seven to end Canada's <a href="https://www.benzinga.com/news/sports/25/06/45783102/canadas-32-year-stanley-cup-drought-could-end-in-2025-oilers-vs-panthers-odds-schedule-how-to-watch">32-year Stanley Cup drought</a>. Game 6 for the Stanley Cup finals airs Tuesday at 8 p.m. ET on TNT and truTV, along with streaming on Max, all units of Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>).
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45325816/unfavorable-sports-outcomes-have-negatively-affected-draftkings-outlook-analyst">Unfavorable Sports Outcomes Have Negatively Affected DraftKings&#8217; Outlook: Analyst</a></li>
</ul>
Photo: Man looking at computer via Shutterstock

Sports Betting

Sports

Media

DKNG

Unemployed 24-Year-Old Nervously Awaits Potential $270K Win From $13 Bet: Here's The NHL, NBA Teams Needed To Cash Out

Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) has outperformed the market over the past 15 years by 4.22% on an annualized basis producing an average annual return of 16.26%. Currently, Roper Technologies has a market capitalization of $60.74 billion. 
Buying $1000 In ROP: If an investor had bought $1000 of ROP stock 15 years ago, it would be worth $9,380.76 today based on a price of $565.66 for ROP at the time of writing.
<h3>Roper Technologies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750113912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Shaquille O'Neal wasn't supposed to be a doctor. Not when he was a fifth grader throwing spit wads, fighting kids, and getting suspended with the warning from his father that he was on track to be "nothing in life." Not when he was getting mocked with names like "<a href="https://www.benzinga.com/personal-finance/management/25/06/45937159/a-geek-saved-my-life-shaq-says-he-was-a-bully-with-a-stutter-nicknamed-shaquille-sasquatch-and-thought-hed-never-be-smart-enough-to-succeed">Shaquille Sasquatch</a>" and struggling to pass a government class.
But somewhere between being called a "big dummy" and becoming a four-time NBA champion, Shaq made a decision—he wasn't just going to be a baller. He was going to be the one in the boardroom who knew exactly what was going on.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
But by 2015, <a href="https://youtu.be/Mza5tTgh9hA?si=3ruv5rkBbOQKkZoI">sitting across from journalist Graham Bensinger</a>, Shaq had a very different kind of flex.
"I go to a business meeting… they talk to my guy," Shaq said. "And I found that to be disrespectful. I'm making the final decision anyway."
He didn't like being underestimated—especially not in business.
That's when O'Neal, already a multimillionaire, went back to school. First, he earned his bachelor's degree in 2000. Then he chased a master's of business administration from the University of Phoenix. His reason? Simple. He wanted respect.
"Talk to me now about the terms… about the JV… all that stuff. Talk to me about it."
And then came the PhD.
"My mom comes and she set me up. She's like, ‘You know we don't have no doctors in the family.' So I'm like, okay, I'll be back."
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
It wasn't just a flex—though getting called "Dr. O'Neal" during a parent-teacher conference certainly didn't hurt.
"I'm looking at my son, <a href="https://www.benzinga.com/personal-finance/24/08/40658562/nba-legend-shaq-tells-his-kids-in-order-to-get-my-cheese-you-have-to-present-me-with-two-degrees">and my son's looking really proud</a>—not only is he proud that I'm the Shaqster… he's proud his daddy is a doctor."
Shaq's educational journey wasn't some PR stunt. It was a tactical move by a man who once felt too shy to even try, too scared to compete with the "smart kids." He credits a high school classmate—nicknamed McDougall—for tutoring him and showing him that school wasn't the enemy.
"That nerd saved my life," he said. "Now I'm a nerd and a geek."
He leaned into it. He started sitting in business meetings and setting up what he called the "Shaq Summit," a yearly gathering of his brand partners. Some companies came ready to walk away—until they saw the vision.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Now? Shaq's endorsements, partnerships, and investments rake in more annually than his NBA salary ever did. But it's never been about the money.
"What motivates me is just having fun," he said. "Being in partnership with somebody really motivates me."
He's even considering law school—not to practice law, but to own the room when he launches his own law firm one day.
"If I just buy a building and put my name on it… they're gonna talk over my head. But if I also have a law degree? I'm in charge."
From spitballs to subchapter S-corps, Shaquille O'Neal didn't just rewrite the script. He rewrote the résumé. And <a href="https://www.benzinga.com/25/05/45601247/shaq-owned-155-five-guys-but-had-no-clue-how-to-run-them-so-he-turned-to-a-mcdonalds-manager-who-hooked-him-up-during-his-nba-days-into-a-partner">Dr. O'Neal is just getting started</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Don't Talk To My Agent—Talk To Me': NBA Legend Shaq Says He Got His PhD So Executives Would Stop Talking Over His Head in Business Meetings

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 20 years by 5.45% on an annualized basis producing an average annual return of 13.86%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion. 
Buying $100 In CORT: If an investor had bought $100 of CORT stock 20 years ago, it would be worth $1,438.13 today based on a price of $70.90 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750113012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-06-16/softbank-seeks-to-raise-4-9-billion-in-t-mobile-share-sale-mbzn3ujs" title="https://www.bloomberg.com/news/articles/2025-06-16/softbank-seeks-to-raise-4-9-billion-in-t-mobile-share-sale-mbzn3ujs">https://www.bloomberg.com/news/articles/2025-06-16/softbank-seeks-to-raise-4-9-billion-in-t-mobile-share-sale-mbzn3ujs</a>

Asset Sales

SFTBY

TMUS

'SoftBank Seeks to Raise $4.9 Billion in T-Mobile Share Sale' - Bloomberg News

<a href="https://www.cnbc.com/2025/06/16/openai-wins-200-million-us-defense-contract.html" title="https://www.cnbc.com/2025/06/16/openai-wins-200-million-us-defense-contract.html">https://www.cnbc.com/2025/06/16/openai-wins-200-million-us-defense-contract.html</a>

Contracts

MSFT

'OpenAI Wins $200M U.S. Defense Contract' - CNBC

Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) released its second-quarter results after Monday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/06/n45963117/lennar-reports-second-quarter-2025-results">from the quarter. </a>
The Details: Lennar reported quarterly earnings of $1.90 per share, which missed the Street estimate of $1.94. Quarterly revenue of $8.38 billion beat the analyst consensus estimate of $8.16 billion.
Read Next:<a href="https://www.benzinga.com/markets/market-summary/25/06/45798808/trump-announces-china-trade-talks-tesla-stock-slumps-whats-driving-markets-thursday?utm_source=articleShare"> </a><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45851086/these-are-the-3-hottest-stock-market-themes-trending-now?utm_source=articleShare">These Are The 3 Hottest Stock Market Themes Trending Now</a>
For the second quarter, Lennar reported: 
<ul class="wp-block-list">
<li>New orders increased 6% to 22,601 homes.</li>
<li>Backlog of 15,538 homes with a dollar value of&nbsp;$6.5 billion.</li>
<li>Deliveries increased 2% to 20,131 homes.</li>
<li>Homebuilding operating earnings of&nbsp;$728 million 
<ul class="wp-block-list">
<li>Gross margin on home sales of 17.8%.</li>
<li>SG&amp;A expenses as a percentage of revenues from home sales of 8.8%.</li>
<li>Net margin on home sales of 8.9%.</li>
</ul>
</li>
<li>Financial Services operating earnings of&nbsp;$157 million.</li>
</ul>
&#8220;While we continue to see softness in the housing market due to affordability challenges and a decline in consumer confidence, we adhered to our strategy of driving starts, sales, and closings in order to build long-term efficiencies in our business,&#8221; Stuart Miller, Co-CEO of Lennar, said.
LEN Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Lennar stock was up 2.58% at $112.32 in Monday's extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb?utm_source=articleShare">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Earnings

After-Hours Center

Movers

Real Estate

Lennar Reports Mixed Q2 Results: EPS Miss, Revenues Beat

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 10 years by 3.86% on an annualized basis producing an average annual return of 14.87%. Currently, Domino's Pizza has a market capitalization of $15.56 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 10 years ago, it would be worth $3,991.31 today based on a price of $454.45 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750112111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Guidance
The following are the Company's expected results of its homebuilding and financial services activities for the third quarter of 2025:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">New Orders</td>
<td colspan="1" rowspan="1">22,000 - 23,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Deliveries</td>
<td colspan="1" rowspan="1">22,000 - 23,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Sales Price</td>
<td colspan="1" rowspan="1">$380,000 - $385,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin % on Home Sales</td>
<td colspan="1" rowspan="1">Approximately 18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SG&amp;A as a % of Home Sales</td>
<td colspan="1" rowspan="1">8.0% - 8.2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Financial Services Operating Earnings</td>
<td colspan="1" rowspan="1">$175 million - $180 million</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Lennar Sees Q3 2025 Homebuilding Deliveries And New Orders Of 22,000 - 23,000; Average Sales Price $380K - $385K

Transaction marks latest infrastructure investment in ANZ and renewable energy investment in APAC
KKR, a leading global investment firm, today announced the signing of definitive agreements to acquire Zenith Energy ("Zenith" or the "Company"), a leading independent power producer ("IPP"), from a consortium including Pacific Equity Partners, OPSEU Pension Trust ("OPTrust"), and Foresight Group (together the "Consortium"), with Zenith's founder and management retaining a minority stake. KKR's investment will position Zenith well for continued long-term growth on the back of favorable sector fundamentals and macro tailwinds.

KKR To Acquire Zenith Energy; No Financial Terms Disclosed

<a href="https://www.whitehouse.gov/presidential-actions/2025/06/implementing-the-general-terms-of-the-united-states-of-america-united-kingdom-economic-prosperity-deal/">https://www.whitehouse.gov/presidential-actions/2025/06/implementing-the-general-terms-of-the-united-states-of-america-united-kingdom-economic-prosperity-deal/</a>

Politics

General

White House Says Imports Of Automobiles Within Tariff-Rate Quota That Would Otherwise Be Subject To 25% Tariff Shall Instead Be Subject To Combined Tariff Of 10%; Trade Deal Repeals Tariffs On UK Aerospace Industry Imposed In Three Previous Executive Orders

Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#TSX">BLDP</a>) today announced a planned leadership transition. After more than a decade of transformative leadership, Randy MacEwen will step down as President and Chief Executive Officer, with Marty Neese assuming the position effective July 7, 2025.
 &nbsp;

Management

BLDP

TSX:BLDP

Ballard Power Systems Announces CEO Transition As Randy MacEwen Steps Down; Marty Neese To Assume Role On July 7, 2025

Economics

White House Says U.S. Intends To Promptly Construct A Quota At Most-Favored-Nation Rates For Steel And Aluminum Articles And Certain Derivative Steel And Aluminum Articles That Are Products Of The UK;  U.S., UK Committed To Strengthen Aerospace And Aircraft Manufacturing Supply Chains By Establishing Tariff-Free Bilateral Trade In Certain Aerospace Products

Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>, HKEX: 9961))) ("Trip.com Group" or the "Company"), a leading one-stop travel service provider for accommodation reservation, transportation ticketing, packaged tours and corporate travel management, today announced that&nbsp;the Company has entered into a share repurchase agreement with MakeMyTrip Limited, an investee of the Company, to sell a portion of the Class B ordinary shares that the Company holds to MakeMyTrip for cancellation. This is part of the Company's efforts to optimize its investment portfolio and enhance shareholder returns. Following completion of the proposed repurchase, the Company will remain the largest minority shareholder of MakeMyTrip and continue to support the growth of MakeMyTrip. To fund the proposed repurchase,&nbsp;MakeMyTrip launched an offering of convertible senior notes pursuant to Rule 144A under the U.S. Securities Act of 1933 and a concurrent underwritten public offering of ordinary shares. In connection with the offerings, the Company has agreed to a lock-up period of 180 days with customary exceptions.

TCOM

Trip.com Group To Sell Portion Of MakeMyTrip Shares Back To Company For Cancellation In Strategic Repurchase Deal Aimed At Portfolio Optimization

White House Says United States Intends To Create An Annual Quota Of 100,000 Vehicles For United Kingdom Automotive Imports At A 10 Percent Tariff Rate; U.S., UK Committed To Negotiate Significantly Preferential Treatment Outcomes On Pharmaceuticals And Ingredients Of UK, Contingent On Findings Of An Investigation

During the last three months, 8 analysts shared their evaluations of Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Federal Realty Investment and provided 12-month price targets. The average target is $110.5, accompanied by a high estimate of $120.00 and a low estimate of $103.00. This current average represents a 9.05% decrease from the previous average price target of $121.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1750111284_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Federal Realty Investment by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>RJ Milligan</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$113.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$111.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Michael Bilerman</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Dori Kesten</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Federal Realty Investment. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Federal Realty Investment compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Federal Realty Investment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Federal Realty Investment's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Federal Realty Investment analyst ratings.</a>
<h2>Unveiling the Story Behind Federal Realty Investment</h2>
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 26.8 million square feet of retail space and over 3,100 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
<h3>Financial Milestones: Federal Realty Investment's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Federal Realty Investment displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 6.12%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: Federal Realty Investment's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.87%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Federal Realty Investment's ROE excels beyond industry benchmarks, reaching 2.03%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Federal Realty Investment's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.72% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.52.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 8 Analyst Ratings Have To Say About Federal Realty Investment

10 analysts have expressed a variety of opinions on Camping World Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $23.00, and a low estimate of $15.00. Observing a downward trend, the current average is 11.63% lower than the prior average price target of $21.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1750111277_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Camping World Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Noah Zatzkin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Noah Zatzkin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Camping World Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Camping World Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Camping World Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Camping World Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CWH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Camping World Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Camping World Holdings: A Closer Look</h2>
Camping World Holdings Inc is a retailer of RVs and related products and services. The company has two reportable segments; the Good Sam Services and Plans segment, which includes the sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories; and the RV and Outdoor Retail segment, which generates maximum revenue and includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, business to business distribution of RV furniture, etc.
<h3>Camping World Holdings: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Camping World Holdings's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 3.63%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Camping World Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.87%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Camping World Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.86%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Camping World Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Camping World Holdings's debt-to-equity ratio surpasses industry norms, standing at 12.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Camping World Holdings In The Eyes Of 10 Experts

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.0, a high estimate of $11.00, and a low estimate of $5.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.0%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750111270_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Recursion Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Recursion Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Recursion Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Recursion Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Recursion Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RXRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Recursion Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Recursion Pharmaceuticals</h2>
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
<h3>Financial Insights: Recursion Pharmaceuticals</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Recursion Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 9.84%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Recursion Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -1366.49%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -20.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Recursion Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.71%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Recursion Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RXRX

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts

8 analysts have shared their evaluations of DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $98.38, a high estimate of $106.00, and a low estimate of $85.00. Surpassing the previous average price target of $98.00, the current average has increased by 0.39%.
<img src="https://www.benzinga.com/files/images/story/2025/1750111248_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of DexCom's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$102.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$104.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$93.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$85.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of DexCom's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DexCom's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DexCom analyst ratings.</a>
<h2>About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>DexCom: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: DexCom's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 12.49%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: DexCom's net margin is impressive, surpassing industry averages. With a net margin of 10.17%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): DexCom's ROE stands out, surpassing industry averages. With an impressive ROE of 4.82%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 1.59%. This signifies efficient management of assets and strong financial health.
Debt Management: DexCom's debt-to-equity ratio surpasses industry norms, standing at 1.14. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

Expert Outlook: DexCom Through The Eyes Of 8 Analysts

Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.29, with a high estimate of $25.00 and a low estimate of $16.00. Observing a downward trend, the current average is 11.15% lower than the prior average price target of $21.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1750111240_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Safehold among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Richard Hill</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Safehold. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Safehold compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Safehold's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Safehold's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAFE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Safehold analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Safehold Better</h2>
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
<h3>Safehold's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Safehold's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 4.79%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Safehold's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 30.06%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.25%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Safehold's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.81, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAFE

The Analyst Verdict: Safehold In The Eyes Of 7 Experts

Press Releases

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Participation in 2025 BIO International Convention

ENVB

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

CNS Pharma

China Pharma Holding

Evoke Pharma

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Comments

Enveric Biosciences

Enveric Biosciences (ENVB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO